{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.088","value":"0.43"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"A subset of high risk prostate cancer participants planned for radical prostatectomy with pelvic lymph node dissection (Cohort A) participated in the pharmacokinetic portion of the study.","id":"OG000","title":"Pharmacokinetic Subset of High Risk Prostate Cancer Participants (Cohort A)"}],"paramType":"MEAN","populationDescription":"Ten (10) participants from a single investigational site with high risk localized prostate cancer scheduled to undergo radical prostatectomy with pelvic lymph node dissection (Cohort A) agreed and were consented to participate in the PK portion of the study.","reportingStatus":"POSTED","timeFrame":"Samples were collected at 0, 5, 15, 30, 60, 120, 240, 360, and 480 minutes after administration of 18F-DCFPyL.","title":"Peak Plasma Concentration (Cmax) of 18F-DCFPyL in a Subset of Participants","type":"SECONDARY","unitOfMeasure":"µCi/mL"}